Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 23;45(1):32.
doi: 10.1007/s10875-024-01818-2.

Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders

Affiliations

Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders

María Palacios-Ortega et al. J Clin Immunol. .

Erratum in

  • Correction to: Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders.
    Palacios-Ortega M, Guerra-Galán T, Jiménez-Huete A, García-Aznar JM, Pérez-Guzmán M, Mansilla-Ruiz MD, Mendiola ÁV, López CP, Hornero EM, Rodriguez AP, Cortijo AP, Zarzuela MP, Morales MM, Mandly EA, Cárdenas MC, Carrero A, García CJ, Bolaños E, Íñigo B, Medina F, de la Fuente E, Ochoa-Grullón J, García-Solís B, García-Carmona Y, Fernández-Arquero M, Benavente-Cuesta C, de Diego RP, Rider N, Sánchez-Ramón S. Palacios-Ortega M, et al. J Clin Immunol. 2025 Feb 7;45(1):72. doi: 10.1007/s10875-025-01865-3. J Clin Immunol. 2025. PMID: 39918595 Free PMC article. No abstract available.

Abstract

Distinguishing between primary (PID) and secondary (SID) immunodeficiencies, particularly in relation to hematological B-cell lymphoproliferative disorders (B-CLPD), poses a major clinical challenge. We aimed to analyze and define the clinical and laboratory variables in SID patients associated with B-CLPD, identifying overlaps with late-onset PIDs, which could potentially improve diagnostic precision and prognostic assessment. We studied 37 clinical/laboratory variables in 151 SID patients with B-CLPD. Patients were classified as "Suspected PID Group" when having recurrent-severe infections prior to the B-CLPD and/or hypogammaglobulinemia according to key ESID criteria for PID. Bivariate association analyses showed significant statistical differences between "Suspected PID"- and "SID"-groups in 10 out of 37 variables analyzed, with "Suspected PID" showing higher frequencies of childhood recurrent-severe infections, family history of B-CLPD, significantly lower serum Free Light Chain (sFLC), immunoglobulin concentrations, lower total leukocyte, and switch-memory B-cell counts at baseline. Rpart machine learning algorithm was performed to potentially create a model to differentiate both groups. The model developed a decision tree with two major variables in order of relevance: sum κ + λ and history of severe-recurrent infections in childhood, with high sensitivity 89.5%, specificity 100%, and accuracy 91.8% for PID prediction. Identifying significant clinical and immunological variables can aid in the difficult task of recognizing late-onset PIDs among SID patients, emphasizing the value of a comprehensive immunological evaluation. The differences between "Suspected PID" and SID groups, highlight the need of early, tailored diagnostic and treatment strategies for personalized patient management and follow up.

Keywords: Artificial intelligence; B cell chronic lymphoproliferative disorders, secondary immunodeficiency; Clinical diagnosis; Early detection; Primary immunodeficiencies.

PubMed Disclaimer

Conflict of interest statement

JMG-A is an employee of Health in Code S.L.. The rest of authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Fig. 1
Fig. 1
Comparison of serum Free Light Chain sum k + λ distribution and median levels between “Suspected-PID” group and “SID” group. Statistically significant difference with p < 0.001 is represented with ***. Figure made with GraphPad Prism 9
Fig. 2
Fig. 2
Tree decision model for early detection of “Suspected PID” patients with diagnosis of SID. Model created through Rpart algorithm

Similar articles

References

    1. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507. - PMC - PubMed
    1. Tiri A, et al. Inborn errors of immunity and cancer. Biology (Basel). 2021;10:1–17. - PMC - PubMed
    1. Otani IM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI primary immunodeficiency and altered Immune Response committees. J Allergy Clin Immunol. 2022;149:1525–60. - PubMed
    1. Riaz IB, Faridi W, Patnaik MM, Abraham RS. A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). Front Immunol. 2019;16(10):777. - PMC - PubMed
    1. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7. - PMC - PubMed

Publication types

LinkOut - more resources